At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 400 target
Drug / intervention
AMG 073 +1 moredrug
Likely dose
AMG 073 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis
In Brief
A Phase 3 clinical trial evaluating AMG 073 and Placebo for Secondary Hyperparathyroidism and End Stage Renal Disease. Completed, enrolled 400 participants.
Detailed Summary
This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2001
First PostedMay 2002
Primary CompletionMar 2003
TodayJul 2026
First PostedMay 20, 2002
Enrollment StartDec 1, 2001
Primary CompletionMar 1, 2003
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 24.1 years ago
Interventions
AMG 073drug
30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
Placebodrug
30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally